Search CatalystAlert
Search for companies, drugs, and catalysts
Search CatalystAlert
Search for companies, drugs, and catalysts
Search for companies, drugs, and catalysts
Search for companies, drugs, and catalysts
Pharmaceutical Preparations · market cap $1.2B
Research and calibrated estimates, not financial advice — verify before acting.
| Asset | Phase | Indication |
|---|---|---|
| PRAM9 | Phase 2 | Diabetes Mellitus, Type 1 |
| G-Pen | Phase 3 | Insulin Hypoglycemia |
| Novo Nordisk GlucaGen® | Phase 2 | Hypoglycemia |
| levothyroxine sodium | Phase 2 | Hypothyroidism |
| G-Pump™ (glucagon infusion) | Phase 2 | Hypoglycemia |
| Glucagon | Phase 3 | Diabetes Mellitus, Type 1 |
| Glucagon RTU | Phase 2 | Hyperinsulinemic Hypoglycemia |
| Lilly Glucagon | Phase 3 | Insulin Hypoglycemia |
| Glucagon RTU Injection With Insulin Pump Reduction | Phase 2 | Hypoglycemia |
| G-Pen (glucagon injection) | Phase 3 | Hypoglycemia |
| G-Pen Mini™ (glucagon injection) | Phase 2 | Hypoglycemia |
| G-Pen(TM) 1 mg | Phase 2 | Hypoglycemia |
Daily closes through 2026-07-02. Realized vol annualized; max drawdown over ~2 years.
The full dossier is a Pro feature
Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.
See ProApproval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.
Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, Financial Modeling Prep). Compiled by CeliA. Not financial advice.